Equity Research on Pfizer Inc. and Bristol-Myers Squibb Co. - Major Drug Manufacturers Focus on R&D and Emerging Markets as Patent Expiries Hit
(firmenpresse) - JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 11/22/11 -- offers investors comprehensive research on the Drug Manufacturers - Major industry and has completed analytical research on (NYSE: PFE) and (NYSE: BMY). Register with us today at to have free access to these researches.
With patent expiry dates looming for a number of high grossing products, major drug manufacturers such as Pfizer Inc. and Bristol-Myers Squibb Co. are looking to new products and markets to try and fill the void. This will be no small task for some, as products such as Pfizer's Lipitor, which accounts for a large percentage of annual sales for the company, are set to expire this year. Register now at to have free access to our reports on the Drug Manufacturers - Major industry.
is an online platform where investors doing their due-diligence on the Drug Manufacturers - Major industry can have easy and free access to our analyst research and opinions on Pfizer Inc. and Bristol-Myers Squibb Co.; all investors need to do is register for a complimentary membership at .
Patent expiry is a way of life for drug manufacturers however, and new products and areas are being looked into in an effort to keep revenues going. Companies like Pfizer and Bristol-Myers Squibb have both been doing well in the sales department, recently reporting increased year over year 3rd quarter sales figures. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.
In an effort to increase sales, companies have been focusing their attention on Europe as well as Latin America. EU approval is essential for those trying to bring new drugs to market, and Pfizer recently announced they have been approved in the EU for their drug Vyndaqel. Investors looking for free research on are welcome to sign up at .
Bristol-Myers Squibb has also been making expansion moves, announcing that they have entered into a technology transfer agreement with the Ministry of Health in Brazil that will increase access to their drug Reyataz. Investors looking for free research on are welcome to sign up at .
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.11.2011 - 13:00 Uhr
Sprache: Deutsch
News-ID 90076
Anzahl Zeichen: 0
contact information:
Town:
JOHANNESBURG, SOUTH AFRICA
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 172 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Equity Research on Pfizer Inc. and Bristol-Myers Squibb Co. - Major Drug Manufacturers Focus on R&D and Emerging Markets as Patent Expiries Hit"
steht unter der journalistisch-redaktionellen Verantwortung von
StockCall (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
